ImmusanT, Inc.

Approval in 2011 of Bristol-Myers Squibb Co. 's CTLA-4 checkpoint inhibitor Yervoy (ipilimumab) in melanoma signaled the start of the immunotherapy revolution in the field of cancer therapy, foll

Derived from Strategic Transactions , Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biophar

Five big investments in health care and life science funds since the end of October delivered more than $1bn in new financing for companies developing biopharmaceuticals and related technology. The ne

Start-Up Execs Acutus Medical Inc. Martin Chambers To: Chief Commercial Officer (September) From: VP, Global Sales, Spinal Modulation Inc. Phone: 858-673-1621 John Dahldorf To: CFO (September)